697 related articles for article (PubMed ID: 15004761)
1. Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: clinical significance.
Ghisetti V; Marzano A; Zamboni F; Barbui A; Franchello A; Gaia S; Marchiaro G; Salizzoni M; Rizzetto M
Liver Transpl; 2004 Mar; 10(3):356-62. PubMed ID: 15004761
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.
Castells L; Vargas V; Rodríguez F; Allende H; Buti M; Sánchez-Avila JF; Jardí R; Margarit C; Pumarola T; Esteban R; Guardia J
Liver Transpl; 2002 Oct; 8(10):892-900. PubMed ID: 12360430
[TBL] [Abstract][Full Text] [Related]
3. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.
Su WJ; Ho MC; Ni YH; Chen HL; Hu RH; Wu YM; Chang MH; Lee PH
J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):203-8. PubMed ID: 19179883
[TBL] [Abstract][Full Text] [Related]
4. Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure.
Abdelmalek MF; Pasha TM; Zein NN; Persing DH; Wiesner RH; Douglas DD
Liver Transpl; 2003 Dec; 9(12):1253-7. PubMed ID: 14625824
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
[TBL] [Abstract][Full Text] [Related]
6. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts.
Vizzini G; Gruttadauria S; Volpes R; D'Antoni A; Pietrosi G; Filì D; Petridis I; Pagano D; Tuzzolino F; Santonocito MM; Gridelli B
Clin Transplant; 2011; 25(1):E77-81. PubMed ID: 21039887
[TBL] [Abstract][Full Text] [Related]
7. HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma.
Momosaki S; Nakashima Y; Kojiro M; Tabor E
J Viral Hepat; 2005 May; 12(3):325-9. PubMed ID: 15850475
[TBL] [Abstract][Full Text] [Related]
8. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population.
Prieto M; Gómez MD; Berenguer M; Córdoba J; Rayón JM; Pastor M; García-Herola A; Nicolás D; Carrasco D; Orbis JF; Mir J; Berenguer J
Liver Transpl; 2001 Jan; 7(1):51-8. PubMed ID: 11150423
[TBL] [Abstract][Full Text] [Related]
9. Clinical course of de novo hepatitis B infection after pediatric liver transplantation.
Su WJ; Ho MC; Ni YH; Wu JF; Jeng YM; Chen HL; Wu YM; Hu RH; Chang MH; Lee PH
Liver Transpl; 2010 Feb; 16(2):215-21. PubMed ID: 20104496
[TBL] [Abstract][Full Text] [Related]
10. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection.
Franchello A; Ghisetti V; Marzano A; Romagnoli R; Salizzoni M
Liver Transpl; 2005 Aug; 11(8):922-8. PubMed ID: 16035057
[TBL] [Abstract][Full Text] [Related]
11. Outcome of hepatitis B and C virus infection on graft function after renal transplantation.
Behzad-Behbahani A; Mojiri A; Tabei SZ; Farhadi-Andarabi A; Pouransari R; Yaghobi R; Rahsaz M; Banihashemi M; Malek-Hosseini SA; Javid A; Bahador A; Reisjalali A; Behzadi S; Salehipour M; Salahl A; Davari R; Janghorban P; Torb A; Salah AR
Transplant Proc; 2005 Sep; 37(7):3045-7. PubMed ID: 16213299
[TBL] [Abstract][Full Text] [Related]
12. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection.
Zerbini A; Pilli M; Boni C; Fisicaro P; Penna A; Di Vincenzo P; Giuberti T; Orlandini A; Raffa G; Pollicino T; Raimondo G; Ferrari C; Missale G
Gastroenterology; 2008 May; 134(5):1470-81. PubMed ID: 18355815
[TBL] [Abstract][Full Text] [Related]
13. Use of anti-HBc positive allografts in adult liver transplantation: toward a safer way to expand the donor pool.
Donataccio D; Roggen F; De Reyck C; Verbaandert C; Bodeus M; Lerut J
Transpl Int; 2006 Jan; 19(1):38-43. PubMed ID: 16359375
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus infection in allogeneic bone marrow transplantation.
Ustün C; Koç H; Karayalcin S; Akyol G; Gürman G; Ilhan O; Akan H; Ozcan M; Arslan O; Konuk N; Uysal A; Beksaç M
Bone Marrow Transplant; 1997 Aug; 20(4):289-96. PubMed ID: 9285543
[TBL] [Abstract][Full Text] [Related]
15. Liver transplantation with allografts from hepatitis B core antibody-positive donors: a new approach.
Fábrega E; García-Suarez C; Guerra A; Orive A; Casafont F; Crespo J; Pons-Romero F
Liver Transpl; 2003 Sep; 9(9):916-20. PubMed ID: 12942452
[TBL] [Abstract][Full Text] [Related]
16. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy.
Cohen Stuart JW; Velema M; Schuurman R; Boucher CA; Hoepelman AI
J Med Virol; 2009 Mar; 81(3):441-5. PubMed ID: 19152397
[TBL] [Abstract][Full Text] [Related]
17. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy.
Hui CK; Cheung WW; Zhang HY; Au WY; Yueng YH; Leung AY; Leung N; Luk JM; Lie AK; Kwong YL; Liang R; Lau GK
Gastroenterology; 2006 Jul; 131(1):59-68. PubMed ID: 16831590
[TBL] [Abstract][Full Text] [Related]
18. Severe clinical course of de novo hepatitis B infection after liver transplantation.
Crespo J; Fábrega E; Casafont F; Rivero M; Heras G; de la Peña J; de la Cruz F; Pons-Romero F
Liver Transpl Surg; 1999 May; 5(3):175-83. PubMed ID: 10226107
[TBL] [Abstract][Full Text] [Related]
19. Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation.
Lu SC; Yan LN; Li B; Wen TF; Zhao JC; Cheng NS; Liu C; Liu J; Wang XB; Li XD; Qin S; Zhao LS; Lei BJ; Zhang XH
Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):26-32. PubMed ID: 14969833
[TBL] [Abstract][Full Text] [Related]
20. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
